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Abstract
Objective To assess the performance of one-view digital
breast tomosynthesis (DBT) in breast cancer screening.
Methods TheMalmö Breast Tomosynthesis Screening Trial is
a prospective population-based one-arm study with a planned
inclusion of 15000 participants; a random sample of women
aged 40–74 years eligible for the screening programme. This
is an explorative analysis of the first half of the study popula-
tion (n=7500). Participants underwent one-view DBT and
two-view digital mammography (DM), with independent dou-
ble reading and scoring. Primary outcome measures were de-
tection rate, recall rate and positive predictive value (PPV).
McNemar's test with 95 % confidence intervals was used.
Results Breast cancer was found in sixty-eight women. Of
these, 46 cases were detected by both modalities, 21 by
DBT alone and one by DM alone. The detection rate for
one-view DBT was 8.9/1000 screens (95 % CI 6.9 to 11.3)
and 6.3/1000 screens (4.6 to 8.3) for two-view DM (p<
0.0001). The recall rate after arbitration was 3.8 % (3.3 to
4.2) for DBT and 2.6 % (2.3 to 3.0) for DM (p<0.0001).
The PPV was 24 % for both DBT and DM.
Conclusion Our results suggest that one-view DBT might be
feasible as a stand-alone screening modality.
Key Points
• One-view DBT as a stand-alone breast cancer screening
modality has not been investigated.
•One-viewDBTincreased the cancerdetection rate significantly.
• The recall rate increased significantly but was still low.
• Breast cancer screening with one-view DBTas a stand-alone
modality seems feasible.
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Introduction
Population-based breast cancer screening with digital mam-
mography (DM) has the potential to reduce breast cancer mor-
tality [1]. Still, 15-30 % of all cancers may be missed, mainly
due to the anatomic noise of the breast, i.e., normal breast
tissue overlapping and obscuring the lesion of interest [2, 3].
This applies especially to dense breasts [4]. In recent years,
digital breast tomosynthesis (DBT) has been developed as a
three-dimensional mammographic technique with the aim to
reduce the adverse effect of overlapping tissue [5, 6]. Typical-
ly, a DM screen is obtained in two projections. The DBT
images can be acquired in either one or two projections, re-
ferred to as one-view or two-view DBT. Several clinical stud-
ies involving enriched populations have shown that the accu-
racy of DBT is superior to DM, demonstrated both when using
one and two views [7–10]. Furthermore, data from two large
population-based screening trials showed that the use of two-
view DBT in combination with two-view DM substantially
improved cancer detection compared to two-view DM
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screening, albeit with conflicting results on recall rates [11,
12]. In the United States, a decrease in recall rate was demon-
strated when using two-view DBT in combination with two-
view DM in large retrospective multicentre screening studies
[13, 14]. The use of one-view DBTor DBTalone in screening
has not hitherto been investigated.
The Malmö Breast Tomosynthesis Screening Trial
(MBTST) is the first trial designed to assess the efficacy of
one-view DBT versus two-view DM, and a combination of
one-view DBT and one-view DM versus two-view DM, in
breast cancer screening. In this explorative study comprising
the first half of the study population, we present our first
results on screening performance measures from the MBTST.
Methods
Study design
The MBTST is a prospective one-arm single-institution study
investigating the use of one-view DBT (mediolateral oblique
(MLO)) alone versus two-view DM (craniocaudal (CC) and
MLO), and a combination of one-view DBT (MLO) and one-
view DM (CC) in a population-based screening programme in
the city of Malmö, Sweden (www.clinicalTrials.gov;
NCT01091545). The study was approved by the Regional
Ethical Review Board at Lund University (Dnr 2009/770)
and the local Radiation Safety Board at Skåne University
Hospital in Malmö. Participating women gave written
informed consent. All participants were offered one-view
DBT (MLO) and two-viewDM (Mammomat Inspiration, Sie-
mens AG, Erlangen, Germany) in a single session upon arrival
at the screening unit. Women who declined to participate in
the study had the DM examination only. This is an explorative
analysis of the first half of the study population with a com-
plete set of DBT and DM screens, i.e., 7500 participants. Out-
come measures for this report were breast cancer detection
rate, recall rate, and positive predictive value.
Population
All women aged 40–74 years are included in the Swedish
breast cancer screening programme, in accordance with rec-
ommendations from the National Board of Health andWelfare
[15]. Women aged 40–55 years are invited every 18 months
and women aged 56–74 years every 24 months. A random
sample of women eligible for the ordinary screening pro-
gramme in the city of Malmö were invited to participate in
the study by a letter added to the screening invitation. Women
were chosen from the population-based screening registry
with the primary aim of obtaining a representative sample of
the population in terms of age distribution. Upon arrival at the
screening unit, the women received further written and oral
information about the study, and if they agreed to participate,
gave written consent. The exclusion criteria were pregnancy
and women not speaking Swedish or English. The first half of
the study population was included from January 2010 to De-
cember 2012.
Image acquisition
Two-view DM images followed by one-view DBT images
were acquired at a single occasion. DBT images were acquired
using the same beam quality and anode/filter combination
(W/Rh) as DM. The automatic exposure control was set to
yield an average glandular dose of 1.2 mGy for DM and
1.6 mGy for DBT (for a standard breast model with an equiv-
alent breast thickness of 53 mm (simulated by a 45 mm
PMMA phantom) measured according to EUREF draft QC
protocol for breast tomosynthesis systems version 1.5 (www.
EUREF.org) including a forward scatter factor (1.06) of the
compression paddle) [16, 17]. Hence, the absorbed dose in a
one-view DBT examination is approximately 70 % of the
absorbed dose in a two-view DM. Each DBT view consisted
of 25 projection images acquired over an angular range of 50
degrees. The images were reconstructed into 1 mm slices
using a generalised filtered back-projection routine [18]. The
DBT examination was performed with reduced compression
of the breast compared to the previously acquired DM image
set, with a goal of a 50 % reduction [19]. This was achieved in
most cases (about 90 %), but sometimes more pressure was
needed to keep especially large breasts in a proper position for
the MLO projection.
Reading procedures
Six readers (five readers with more than 10 years of experi-
ence in breast radiology and one reader with less than 10 years
of experience, mean 26 years, range 8 to 41 years) participated
in the trial. They had undergone individual training in inter-
pretation of DBT images and had participated in
previous reading studies [9, 10]. Readers had also been ex-
posed to DBT as part of clinical problem-solving during a 2-
year period prior to the start of the current study.
The reading included blinded double reading and scoring
in two independent reading arms: Reading arm DBT and
Reading arm DM (Fig. 1). The readers were randomly
assigned to the two reading arms. The findings for DBT and
DM were classified using a 5-point scale: (1) normal, (2) be-
nign findings, (3) non-specific finding with low probability of
malignancy (4) findings suspicious of malignancy, and (5)
findings highly suspicious of malignancy. The scale is similar
to the American College of Radiology’s Breast Imaging
Reporting and Data System (BI-RADS) [20]. The scores were
registered in the Radiology Information System (RIS, Sectra,
Linköping, Sweden). If one or both of the screening
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modalities was given a score of 3 or higher by one of the two
readers, it was referred for arbitration, where at least two
readers re-evaluated the images and decided whether to recall
the woman for further work-up, irrespective of the score on
the other modality. In the event of a woman reporting symp-
toms during the screen examination, e.g., palpable lump or
nipple secretion, the woman could be recalled in spite of neg-
ative imaging findings. Breast density was judged by one
reader in step 3 in Reading arm DM, and classified according
to BI-RADS: (1) fatty, (2) scattered fibroglandular densities,
(3) heterogeneously dense, and (4) dense [20].
Workup
Women recalled for assessment had their workup done at the
breast clinic by the same group of radiologists who were in-
volved in the reading of the DBT and DM screening images.
The assessment usually included additional DM images and
an ultrasound examination and, in the event of a lesion, also a
needle biopsy. Outcomes were assessed by needle biopsy,
surgery or at least one-year follow-up. All cancer cases were
verified through record linkage with the South Swedish Can-
cer Registry.
Statistical analysis
The MBTST was designed to include approximately 15,000
women in order to get an 80 % power, with a two-sided sig-
nificant threshold of 5 %, to demonstrate an increased sensi-
tivity from about 63 % when using DM to 88 % when using
DBT, in a population with a cancer prevalence of 6 per 1000
women. Also, the sample size calculation took into account an
assumed increase in false positive fraction of 20 % with an
equivalent specificity for DM and DBT of 4 %. The calcula-
tions were based on Receiver Operating Characteristic statis-
tical analysis [21]. In order to evaluate the progress of the
clinical trial and the feasibility of our assumptions in the sam-
ple size calculations, we performed this explorative analysis
with screening performance measures of the first half of the
study population. The inclusion of participants with a com-
plete set of DBT and DM examinations gives paired binary
data for all participants. McNemar's test was used to analyse
the paired data of DBT and DM screens for differences in
detection and recall rates with 95 % CIs. Differences in char-
acteristics between cancers detected solely by DBT and all
DM-detected cancers were tested using chi-2 test and Fisher's
exact test, if the sample size was small. Analyses were done
with Stata software (version 13).
Results
Of 10,547 women invited, 7500 participated in the study
(71.1 %) (Fig. 2). The mean age of the participants was
56 years (range 40–76). The number of participants screened
for the first time was estimated to be 1563 women, i.e., 20 %.
The breast density distribution in the study population accord-
ing to BI-RADS was fatty: 20 %; scattered densities: 38 %;
heterogeneously dense: 34 %, and dense: 8 %.
Sixty-seven women were detected with breast cancer in
Reading arm DBT and 47 in Reading arm DM, respectively.
Of these, 46 cancer cases were detected in both reading arms.
Hence, 21 cancer cases were detected by DBT alone and one
cancer by DM alone. The detection rate for Reading arm DBT
and Reading arm DM was 8.9 per 1000 screens (95 % CI 6.9
to 11.3) and 6.3 per 1000 screens (4.6 to 8.3), respectively.
The increase in cancer detection when using DBT relative to
DM was 43 % (95 % CI 21 to 68; p<0.0001). All cancers in
Reading arm DBT were detected in the first reading step, i.e.
by DBT alone. Hence, there were no additional cancers de-
tected by the combination of one-view DBT and one-view
DM, i.e. reading step 2 in the DBT reading arm.
The number of recalled women in Reading arm DBT was
282 and in Reading arm DM 197, respectively. The recall rate
for Reading arm DBTand Reading arm DMwas 3.8 % (95 %
CI 3.3 to 4.2) and 2.6 % (2.3 to 3.0), respectively. The increase
in recall rate when using DBT relative to DMwas 43% (95 %
CI 26 to 62; p<0.0001). The positive predictive value was
24 % (67/282) for DBT as well as for DM (47/197).
The recall rates and number of cancers per reading arm,
related to the positive score before arbitration for each reading
step, are illustrated in Table 1.
All cancers were verified microscopically on surgical spec-
imens, except for one case verified with core biopsy (refused
ADBT (MLO) + DM (CC) + prior DM
DM (MLO, CC) + prior DM + breast density
Arbitration
AArbitration





Fig. 1 Reading procedure flowchart. Blinded double reading and scoring
in independent reading arms. Each step was scored before proceeding to
the next step. A positive score (3–5) in any step qualified the case for
arbitration. Prior DM was a two-view DM. DBT=digital breast
tomosynthesis, DM=digital mammography, MLO=mediolateral oblique
view, CC=craniocaudal view
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surgery). The characteristics of the cancers are summarised in
Table 2.
Seventeen out of 21 DBT alone detected cancers were in-
vasive, ten were grade 2 or 3 and two had lymph node metas-
tases. There were no statistically significant differences in
cancer characteristics between cases detected by DBT alone
and cancers detected by DM in regard to proportions of inva-
sive and in situ cancer, cancer type, histological grade, lymph
node status, breast density, and tumour size. Still, the cancers
detected byDBTalone tended to bemore of histological grade
1, lymph node negative, and of smaller size than DM-detected
cancers. Also, these women were slightly younger. The cases
detected by DBT alone were distributed across all BI-RADS
density categories. A typical cancer detected by DBT alone is
illustrated in Fig. 3.
Discussion
The main findings of this explorative analysis suggest that
one-view DBT may be feasible as a stand-alone technique
for breast cancer screening. Compared with the current gold
standard (DM), DBT was superior in terms of detection rate
and equal in terms of PPV. The DM CC-view did not contrib-
ute to cancer detection but did help in ruling out cancer in a
few cases with stable, benign lesions, as did previous DM
examinations.
The DBTcancer detection rate may seem remarkably high.
However, the current intervention should be regarded as prev-
alence DBT screening. If a new screening technique, which is
superior to DM in terms of cancer detection, is applied, an
effect similar to the one observed in the randomisedmammog-
raphy screening trials will be seen, i.e., a higher detection rate
in the intervention arm compared to the control arm [22]. In
addition, in the current study, approximately 20 % of the pop-
ulation was invited to mammography screening for the first
time, either because of turning 40 or being a newly arrived
immigrant. As a consequence, it is reasonable to expect a
lower detection rate if subsequent screening rounds were
performed.
In the present study there is not enough data for a statistical
comparison of the biological characteristics of the DBT and
DM detected cancers. Even though the rate of detected DCIS
was similar in the two reading arms, the cancers detected by
Invited women n =10547
Women recalled after arbitration n = 282 
Recall rate 3.8 %
Women with cancer n = 67
Detection rate 8.9/1000*
Women recalled after arbitration n = 197
Recall rate 2.6 %
Women with cancer n = 47
Detection rate 6.3/1000*
Participating women with a complete set of DBT 
and DM examinations n = 7500 (71.1 %)
Women recalled after arbitration n = 352
Recall rate 4.7 %
Screen detected cancers n = 68
*p-value <0.0001 (McNemar´s test)
Reading arm DBT Reading arm DM




Table 1 Results of reading procedure by reading arm and reading step.
Reading arm DBT: (reading step 1) one-viewDBTalone, (reading step 2)
the addition of a DM CC-view, (reading step 3) comparison with prior
two-view DM, if available. Reading arm DM: (reading step 1) two-view
DM, (reading step 2) comparison with prior DM. DBT=digital breast
tomosynthesis, DM=digital mammography
Reading arm DBT Reading arm DM
Positive score before arbitration Recalls (n) Recall rate Cancers (n) Recalls (n) Recall rate Cancers (n)
Reading step 1 243 3.2 % 67 166 2.2 % 47
Reading step 2 10 0.1 % 0 2 0.02 0
Reading step 3 4 0.05 % 0 n/a n/a n/a
Symptoms, no imaging finding 25 0.3 % 0 29 0.04 0
Total 282 3.8 %* 67† 197 2.6 %* 47†
*p-value <0.0001 (McNemar’s test)
†p-value <0.0001 (McNemar’s test)
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DBT alone tended to be of lower grade, smaller size and
lymph node negative, compared with DM-detected cancers.
Also, these womenwere slightly younger at diagnosis. It is not
clear whether this represents earlier diagnosis and/or overdi-
agnosis from DBT screening, since the present study was not
designed to address these issues. This question will be further
analysed when the entire study is completed. Our impression
in the present study, as well as from a previous study, is that
DBT is particularly sensitive to the detection of small
spiculated lesions [23]. Such lesions tend to be either low-
grade cancers or benign radial scars, while small high-grade
cancers tend to be less specific in appearance, i.e., non-
specific densities with diffuse borders or well circumscribed
with benign appearance [24]. Furthermore, the cancers detect-
ed by DBT alone were found in both dense and fatty breasts,
which mean that the increased cancer detection rate with DBT
is not solely due to the reduction of the negative effect of
superimposed tissue in dense breasts but also to better lesion
conspicuity in more fatty breasts. These results are in accor-
dance with findings in the two earlier prospective screening
trials [11, 12]. Accordingly, DBT will also enhance benign
lesions and sometimes islands of normal breast parenchyma.
This probably contributed to the significant increase in recall
rate with DBT compared to DM. Even if the recall rate was
Table 2 Summary of cancer characteristics. DBT=digital breast tomosynthesis, DM=digital mammography
Detected DBT total Detected DBT alone* Detected DM total* Detected DM alone
Total 67 21 47 1
Total invasive cancers 58 (87) 17 (81) 41 (87) -
Total in situ cancers 9 (13) 4 (19) 6 (13) 1 (100)
Cancer type
IDC 37 (55) 10 (48) 27 (57) -
DCIS+microfoci of IDC 3 (4) 1 (5) 2 (4) -
DCIS 7 (10) 3 (14) 5 (11) 1 (100)
ILC 9 (13) 3 (14) 6 (13) -
Tub 9 (13) 3 (14) 6 (13) -
LCIS 2 (3) 1 (5) 1 (2) -
Histological grade
Grade 1 24 (36) 10 (48) 14 (30) -
Grade 2 23 (34) 5 (24) 19 (40) 1 (100)
Grade 3 18 (23) 5 (24) 13 (28) -
n/a 2 (3) 1 (5) 1 (2) -
Lymph node status
Positive 14 (21) 2 (10) 12 (26) -
Negative 50 (74) 18 (86) 32 (68) 1 (100)
n/a 3 (4) 1 (5) 3 (6) -
Mean size (range) 16 mm (5–60) 13 mm (6–25) 17 mm (5–60) 8 mm
Mean age (range) 60 yrs (40–74) 58 yrs (43–71) 61 yrs (40–74) 65 yrs
Breast density
Fatty 7 (10) 3 (14) 4 (9) -
Scattered 17 (25) 5 (24) 12 (26) -
Heterogeneous 33 (49) 10 (48) 24 (51) 1 (100)
Dense 10 (15) 3 (14) 7 (15) -
Radiographic appearance
Spiculated mass 51 (76) 16 (76) 35 (74) -
Circumscribed mass 8 (12) 3 (14) 5 (11) -
Architectural distortion 1 (1) 1 (5) 0 (0) -
Microcalcifications 7 (10) 1 (5) 7 (15) 1 (100)
Data are n (%) or range when stated
IDC=invasive ductal carcinoma, DCIS=ductal carcinoma in situ, ILC=invasive lobular carcinoma, Tub=invasive tubular carcinoma,
LCIS=lobular carcinoma in situ
(*)There were no statistically significant differences between the characteristics of the cancers detected by DBT alone and DM total
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higher with DBT, it was still low and in agreement with the
recommendation from the European Guidelines for Quality
Assurance in Breast Cancer Screening and Diagnostic Services
[25]. Several studies have reported a reduced false positive rate
with DBT. However, the baseline recall rate was much higher
in these studies compared with MBTST [11, 13, 14]. Further-
more, the increased recall rate observed in this study was higher
than assumed in the sample size calculation. It is reasonable to
expect that the increase in recall rate will be somewhat lower in
the second half of the study population in line with increased
experience of the readers. Further analysis on recall rates will be
presented after the completion of the MBTST.
Implications for practice
In general, a mass screening technique should be fast, with a
high sensitivity and specificity, reasonably inexpensive, and,
in the case of an X-ray examination, at a low radiation dose.
Accordingly, in the design of the MBTSTwe chose one-view
DBT in the MLO-projection. This projection has been shown
to be the most effective in mammography screening [26]. We
estimate that the reading time for one-view DBT in screening
is about doubled compared to DM. We did not register the
reading time in our study, since the reading and scoring pro-
cedures were specific to the trial and would not reflect the true
time consumption in a normal screening workflow. In a pre-
vious study from our group, we found that the reading time for
one-view DBT (MLO) was roughly 30 s (in an enriched pop-
ulation of clinical and screening cases) [27]. This is about one
third of the reported reading time for the so-called combina-
tion mode — two-view DBT in combination with two-view
DM — used in the Oslo Tomosynthesis Screening Trial [12].
In our study, the radiation dose for one-view DBT
examination was lower than an ordinary two-viewDM screen,
which is satisfactory from a mass screening perspective. Es-
pecially considering that the use of a combination mode, eval-
uated in the other screening trials, gives additional radiation
dose compared to a single modality approach [11, 12]. Still,
the use of a synthetic mammogram derived from the DBT
volume can provide means to sustain a low radiation dose
even with the use of a combination mode.
The reduced compression force used in this study was
much appreciated by the women, according to our examining
technologists. However we did not collect any qualitative data
to verify this statement. The high cancer detection rate in the
current study supports previous results showing that reduced
compression does not significantly compromise image quality
[19]. We believe this is an important advantage of DBT.
Breast cancer mammography screening has been considered
cost-effective [28]. The cost-effectiveness of DBTcompared to
DM in screening for breast cancer has yet to be evaluated, and
is important for future decisions on the introduction of DBT in
screening. So far, it is reasonable to assume that DBT will be
more expensive, but this has to be related to the benefit of
increased cancer detection, and probably earlier detection.
The ultimate measure of screening efficacy is the reduction
of breast cancer mortality. Our study was not designed to
assess differences in breast cancer mortality, for that purpose
a very large randomised screening trial would be needed. An
alternative could be to analyse the relative reduction of inter-
val cancers as a surrogate end-point for screening efficacy. An
estimation of interval cancer rates will be included in future
reports from the MBTST, after the inclusion and follow-up of
the whole study population.
Limitations
A limitation of this study is that it was performed on an urban
Swedish population, and might, therefore, not be representa-
tive for other populations. In addition, the examinations were
performed using one particular brand of tomosynthesis equip-
ment that differs from other commercially available systems.
Also, the readers involved had participated in previous clinical
studies on the accuracy of DBT, and might, therefore, be bi-
ased in favour of DBT. As a consequence, this explorative
analysis will not introduce additional bias to the readers. Fur-
thermore, the limitation of an explorative analysis on half of
the study population is that it does not have an 80 % power in
the statistical analyses.
Conclusion
We found a significant increase in cancer detection rate when
using one-view DBT as a stand-alone screening
modality compared to two-viewDM. The recall rate increased
DBT DM 
Fig. 3 Cancer detected by digital breast tomosynthesis alone. A sixty-
six-year-old asymptomatic woman recalled for findings suspected only
on digital breast tomosynthesis. A 15-mm invasive ductal carcinoma,
histological grade 1 and lymph node negative, was diagnosed at histolog-
ical examination
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significantly but was still low. If one-view DBT is to be used
in mass screening, advantages such as reduced compression
force and lower radiation dose can be gained. Our results
suggest that one-view DBT might be feasible as a stand-
alone breast cancer screening modality.
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